Profile

Susan A. Melin, M.D.Wake Forest Baptist Health

Doctor Rating

4.5 out of 5

161 Ratings
9 Comments

Susan A. Melin, M.D.

Associate Professor,


Clinical Interests

Breast Cancer

Contact Information

New Patient Appointments: 336-716-WAKE
Returning Patient Appointments: 336-713-5440
Department: 336-716-4464

Insurance Accepted »

Education & Training

  • B.S., University of North Carolina-Chapel Hill, 1977
  • M.D., WFU School of Medicine, 1985
  • Residency, Eastern Virginia Medical Schoo, 1988
  • Fellowship, Univ of NC at Chapel Hill, 1991

Memberships

  • North Carolina Medical Society
  • Am Coll Of Physicians
  • Am Medical Assn
  • Am Soc of Clinical Oncology

NPI Number

  • 1528042058
Susan A. Melin, M.D.

Doctor Rating

4.5 out of 5

161 Ratings
9 Comments

Susan A. Melin, M.D.

Associate Professor, Hematology & Oncology
Comprehensive Cancer Center
Office of Women in Medicine and Science

Research Interests

cancer/oncogenesis, drugs/therapeutic agents pharm, women's health issues

Contact Information

Academic: 336-716-7975 | Department: 336-716-4464

Recent Publications

Cowherd S, Miller LD, Melin SA, Akman S, Isom S, Cole J, Pullikuth A, Lawrence JA. A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer. Cancer Biol Ther. 2015;16(5):678-683.

Vitolins MZ, Milliron BJ, Hopkins JO, Fulmer A, Lawrence J, Melin S, Case D. Weight loss intervention in survivors of ER/PR-negative breast cancer. Clin Med Insights Womens Health. 2014;7():17-24.

Ahmed S, Lawrence J, Stewart JH, Melin S, Levine EA, Howard-McNatt M. Does age predict outcome in patients with inflammatory breast cancer?. Am Surg. 2014;80(8):E221-E224.

Cowherd S, Melin S, Akman S, Cole J, Lawrence J. A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic or recurrent breast cancer patients with triple negative disease [abstract]. Cancer Res. 2014;74(19 Suppl):CT302.

Howard-McNatt M, Lawrence J, Melin SA, Levine EA, Shen P, Stewart JH IV. Race and recurrence in women who undergo neoadjuvant chemotherapy for breast cancer. Am J Surg. 2013;205(4):397-401.

Rugo HS, Serrurier K, Melisko M, Glencer A, Hwang J, D'Agostino R, Hutchens S, Esserman L, Melin S. The Dignicap System to prevent alopecia in women receiving chemotherapy for breast cancer [abstract]. Breast. 2013;22(Suppl 1):S119.

Lawrence JA, Akman SA, Melin SA, Case LD, Schwartz GG. Oral paricalcitol (19-nor-1,25-dihydroxyvitamin D2) in women receiving chemotherapy for metastatic breast cancer: a feasibility trial. Cancer Biol Ther. 2013;14(6):476-480.

Drafts BC, Twomley KM, D'Agostino R Jr, Lawrence J, Avis N, Ellis LR, Thohan V, Jordan J, Melin SA, Torti FM, Little WC, Hamilton CA, Hundley WG. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging. 2013;6(8):877-885.

Chaosuwannakit N, D'Agostino R Jr, Hamilton CA, Lane KS, Ntim WO, Lawrence J, Melin SA, Ellis LR, Torti FM, Little WC, Hundley WG. Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol. 2010;28(1):166-172.

Vitolins M, Lesser GJ, Case LD, Williford SK, Giguere JK, Garino A, Naughton MJ, Lively M, Melin SA, Shaw EG. Self-reported compliance compared to biomarker levels of vitamin E in breast cancer patients participating in a CoQ10 clinical trial [abstract]. J Clin Oncol. 2010;28(15 Suppl):e19524.

Twomley K, D'Agostino R Jr, Lawrence J, Melin S, Ellis LR, Stacey B, Hamilton CA, Torti F, Little W, Hundley W. Early and persistent evidence of subclinical cardiovascular injury after receipt of anthracycline chemotherapy [abstract]. Circulation. 2010;122(21 Suppl):A12766.

Chaosuwannakit N, D'Agostino R Jr, Hamilton CA, Lane KS, Ntim WO, Lawrence J, Melin SA, Ellis LR, Torti FM, Little WC, Hundley WG. Subclinical cardiovascular toxicity of anthracyclines identified with cardiovascular magnetic resonance imaging [abstract]. Circulation. 2009;120(18 Suppl):S299.

Ramanathan RK, Picus J, Raftopoulos H, Bernard S, Lockhart AC, Frenette G, Macdonald J, Melin S, Berg D, Brescia F, et al. A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer. Cancer Chemother Pharmacol. 2008;61(3):453-458.

Miller AA, Case D, Harmon M, Savage P, Lesser G, Hurd D, Melin SA. Phase I study of lenalidomide in solid tumors. J Thorac Oncol. 2007;2(5):445-449.

Kim C, Farmer MR, Yacoub J, Monjazeb A, Levine EA, Aklilu M, Geinsinger [sic] KR [Geisinger KR], Mishra G, Melin S, Blackstock AW. Tri-modality therapy for esophageal cancer: mucinous histology is associated with decreased pathologic response rates to neoadjuvant chemoradiation therapy [abstract]. Int J Radiat Oncol Biol Phys. 2007;69(3 Suppl):S267.

Monjazeb AM, Farmer MR, Mattern M, Mebea A, Levine EA, Geisinger KR, Mishra G, Melin S, Blackstock AW. Patterns of failure for esophageal cancer patients optimally staged with 18-F-FDG-PET and observed after chemo-radiotherapy [abstract]. Int J Radiat Oncol Biol Phys. 2007;69(3 Suppl):S274.

Blackstock AW, Mornex F, Partensky C, Descos L, Case LD, Melin SA, Levine EA, Mishra G, Limentani SA, Kachnic LA, et al. Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study. Br J Cancer. 2006;95(3):260-265.

Blackstock AW, Aklilu M, Lovato J, Farmer MR, Mishra G, Melin SA, Oaks T, Geisinger K, Levine EA. Pathologic complete response may not represent the optimal surrogate for survival after preoperative therapy for esophageal cancer. Int J Gastrointest Cancer. 2006;37(1):7-14.

Farmer MR, Yacoub J, Aklilu M, Levine EA, Geisinger K, Mishra G, Melin S, Blackstock AW. Tri-modality therapy for esophageal cancer: hemoglobin levels are prognostic for survival but do not predict response to radiochemotherapy [abstract]. Int J Radiat Oncol Biol Phys. 2006;66(3 Suppl):S269.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Associate Professor, Hematology & Oncology

Clinical Interests

Breast Cancer
Susan A. Melin, M.D.

Susan A. Melin, M.D.

Associate Professor, Hematology & Oncology
Comprehensive Cancer Center
Office of Women in Medicine and Science

Doctor Rating

4.5 out of 5

Susan A. Melin, M.D.161 Ratings
9 Comments

Doctor Ratings

The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Press Ganey Patient Satisfaction Survey

CP concern for questions/worries
4.7
CP efforts to include in decisions
4.7
CP explanations of prob/condition
4.7
CP spoke using clear language
4.8
Friendliness/courtesy of CP
4.7
Likelihood of recommending CP
4.7
Patients' confidence in CP
4.7
Time CP spent with patient
4.5
Wait time at clinic
3.4



Patient Comments

Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.

7/8/2015

Wake Forest is the best hospital that I've been to. I drive 2 1/2 hours just to get the best care that I can, and I sure do. #8. Took time for me to understand. #10. Already have.

5/4/2015

I have recommended this provider and facility to many people. This has been a year to remember but this facility and staff have made it pleasant. I have felt so welcomed and cared for with sincere people. This has definitely made an impression on all of my family and their friends as well. Several people have come here this year as a result of our praising this facility and your staff. I feel like the physicians can be trusted and really listen to your concerns. One of my relatives had to switch to another facility because of the new health care rules with her insurance plan and she is not happy with that. She was use to your level of care and other facilities just do not measure up to your standards of professionalism.

3/23/2015

Very pleased with both the PA and Dr. Melin. Both expressed concern and asked questions about overall health issues.

2/28/2015

Dr. Melin is excellent in answering questions, spending time with me and knowing my health condition.

2/16/2015

Good.

1/12/2015

Dr Melin and her PAs are always very friendly, caring, and helpful.

12/9/2014

dr susan melin is my favorite, my best physician, out of ten physicians/surgeons i see. i have rec'd her to multiple friends who have been diagnosed with CA or family with CA. i have been very lucky to have "found" dr. melin....would not trade her for any other oncologist!!

11/25/2014

Have recommended Dr. Melin to several people.

10/23/2014

Dr. Melin is the best!

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
USNWR 2015-2016Magnet Hospital RecognitionConsumer Choice2014 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.